MEP52308A - Kompozicija tablete pramipeksola sa produženim oslobođenjima - Google Patents

Kompozicija tablete pramipeksola sa produženim oslobođenjima

Info

Publication number: MEP52308A
Authority: ME; Montenegro
Prior art keywords: pramipexole; sustained; release tablet; tablet composition; tablet
Prior art date: 2002-07-25

Application number

MEP-523/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Gregory E Amidon

Loksidh D Ganorkar

John M Heimlich

Ernest J Lee

Robert M Noack

Joseph P Reo

Connie J Skoug

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-25

Filing date

2003-07-25

Publication date

2011-02-10

2003-07-25 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2011-02-10 Publication of MEP52308A publication Critical patent/MEP52308A/hr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

MEP-523/08A 2002-07-25 2003-07-25 Kompozicija tablete pramipeksola sa produženim oslobođenjima MEP52308A (hr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US39844702P	2002-07-25	2002-07-25
US39842702P	2002-07-25	2002-07-25
US47951303P	2003-06-18	2003-06-18
PCT/US2003/023205 WO2004010997A1 (en)	2002-07-25	2003-07-25	Sustained-release tablet composition of pramipexole

Publications (1)

Publication Number	Publication Date
MEP52308A true MEP52308A (hr)	2011-02-10

Family

ID=31192087

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-523/08A MEP52308A (hr)	2002-07-25	2003-07-25	Kompozicija tablete pramipeksola sa produženim oslobođenjima

Country Status (41)

Country	Link
US (2)	US20050226926A1 (hr)
EP (2)	EP1531814B1 (hr)
JP (1)	JP4700963B2 (hr)
KR (1)	KR100712832B1 (hr)
CN (1)	CN1313092C (hr)
AP (1)	AP2201A (hr)
AR (1)	AR040681A1 (hr)
AT (1)	ATE406162T1 (hr)
AU (1)	AU2003261241B2 (hr)
BR (1)	BR0312960A (hr)
CA (1)	CA2492854C (hr)
CR (1)	CR7661A (hr)
CU (1)	CU23440B7 (hr)
CY (1)	CY1110408T1 (hr)
DE (1)	DE60323235D1 (hr)
DK (1)	DK1531814T3 (hr)
EA (2)	EA200702187A1 (hr)
EC (1)	ECSP055568A (hr)
ES (1)	ES2310673T3 (hr)
GE (1)	GEP20074048B (hr)
HK (1)	HK10777456A1 (hr)
HR (1)	HRP20041235B1 (hr)
IL (1)	IL166078A0 (hr)
IS (1)	IS7623A (hr)
MA (1)	MA27328A1 (hr)
ME (1)	MEP52308A (hr)
MX (1)	MXPA05001054A (hr)
MY (1)	MY138846A (hr)
NO (1)	NO334298B1 (hr)
NZ (1)	NZ537790A (hr)
OA (1)	OA13303A (hr)
PA (1)	PA8578301A1 (hr)
PE (1)	PE20040130A1 (hr)
PL (1)	PL215587B1 (hr)
PT (1)	PT1531814E (hr)
RS (1)	RS51719B (hr)
SI (1)	SI1531814T1 (hr)
TW (1)	TWI347849B (hr)
UY (1)	UY27912A1 (hr)
WO (1)	WO2004010997A1 (hr)
ZA (1)	ZA200500439B (hr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
US7157480B2 (en) *	2001-12-11	2007-01-02	University Of Virginia Patent Foundation	Use of pramipexole to treat amyotrophic lateral sclerosis
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
AR040680A1 (es) *	2002-07-25	2005-04-13	Pharmacia Corp	Composicion de tabletas de liberacion sostenida
PE20040134A1 (es) *	2002-07-25	2004-03-06	Pharmacia Corp	Forma de dosificacion de una vez al dia de pramipexol
JP4959191B2 (ja)	2003-07-11	2012-06-20	旭化成ケミカルズ株式会社	機能性澱粉粉末
NZ553645A (en)	2004-08-13	2010-09-30	Boehringer Ingelheim Int	Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ589267A (en) *	2004-08-13	2012-06-29	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
PL1803447T3 (pl) *	2004-09-09	2010-05-31	Psicofarma S A De C V	Kompozycja farmaceutyczna do długotrwałego uwalniania hydralazyny oraz jej zastosowanie wspomagające w leczeniu raka
EP1731514A1 (en) *	2005-06-02	2006-12-13	Sandoz AG	Process for the preparation of Pramipexole
JP2009504748A (ja) *	2005-08-15	2009-02-05	ユニバーシティオブバージニアパテントファウンデーション	Ｒ（＋）プラミペキソールを用いた神経回復
WO2007090882A2 (en) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Pharmaceutical extended release compositions comprising pramipexole
CA2641665A1 (en) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Modified release formulation
US20090098202A1 (en) *	2006-02-10	2009-04-16	Boehringer Ingelheim International Gmbh	Extended Release Formulation
US8518926B2 (en)	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) *	2006-04-10	2007-11-08	Knopp Neurosciences, Inc.	Compositions and methods of using r(+) pramipexole
DK2026803T3 (da) *	2006-05-16	2012-04-16	Knopp Neurosciences Inc	Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
WO2008001204A2 (en) *	2006-06-29	2008-01-03	Antares Pharma Ipl Ag	Transdermal compositions of pramipexole having enhanced permeation properties
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2008224844B2 (en) *	2007-03-14	2012-08-09	Knopp Neurosciences, Inc.	Synthesis of chirally purified substituted benzothiazole diamines
US20100092554A1 (en) *	2007-04-24	2010-04-15	Boehringer Ingelheim International Gmbh	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20080299189A1 (en) *	2007-06-04	2008-12-04	Drugtech Corporation	Controlled release dopamine agonist compositions
CA2725482A1 (en) *	2008-06-09	2009-12-17	Supernus Pharmaceuticals, Inc.	Controlled release formulations of pramipexole
JP2012500283A (ja)	2008-08-19	2012-01-05	ノップニューロサイエンシーズ、インク．	（ｒ）−プラミペキソールを使用した組成物並びにその方法
EP2442655A4 (en) *	2009-06-19	2013-04-03	Knopp Neurosciences Inc	COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
MX2012000096A (es) *	2009-07-02	2012-04-02	Supernus Pharmaceuticals Inc	Un metodo de tratamiento de un trastorno neurologico.
WO2011037976A2 (en) *	2009-09-22	2011-03-31	Dr. Reddy's Laboratories Limited	Pramipexole pharmaceutical formulations
WO2011086182A2 (en)	2010-01-18	2011-07-21	Synthon Bv	Pramipexole extended release tablets
TR201001862A1 (tr)	2010-03-11	2011-10-21	Sanovel �La� San.Ve T�C.A.�.	Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
WO2011148243A1 (en)	2010-05-24	2011-12-01	Lupin Limited	Extended release formulation of pramipexole
KR101307334B1 (ko)	2010-07-02	2013-09-12	주식회사 바이오파마티스	프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (en)	2011-09-06	2013-03-14	Synthon Bv	Pramipexole extended release tablets
WO2013096816A1 (en)	2011-12-22	2013-06-27	Biogen Idec Ma Inc.	Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de)	2012-11-15	2014-05-21	Aristo Pharma GmbH	Pramipexol-Retardtablettenformulierung
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
SI3838271T1 (sl)	2013-07-12	2025-12-31	Areteia Therapeutics, Inc.	Zdravljenje povišanih ravni eozinofilcev in/ali bazofilcev
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
AU2014306683B2 (en)	2013-08-13	2017-10-12	Knopp Biosciences Llc	Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
PT3033081T (pt)	2013-08-13	2021-06-01	Knopp Biosciences Llc	Composições e métodos para o tratamento da urticária crónica
CN103520128B (zh)	2013-10-12	2018-08-21	石家庄杏林锐步医药科技股份有限公司	一种普拉克索的缓释片剂、制备方法及其用途
IL312486B2 (en)	2017-04-10	2025-05-01	Chase Therapeutics Corp	NK1 antagonist combination and method for treating synucleinopathies
EA201992532A1 (ru)	2017-04-24	2020-04-03	Чейс Терапьютикс Корпорейшн	Композиции и способ для лечения депрессии
KR20200026920A (ko)	2017-06-30	2020-03-11	체이스 테라퓨틱스 코포레이션	우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN109316466B (zh) *	2017-07-31	2022-04-05	深圳翰宇药业股份有限公司	一种盐酸普拉克索缓释制剂及其制备方法
CN111212640A (zh)	2017-08-17	2020-05-29	顾自强	单胺抗帕金森药物的双羟萘酸盐、其制备方法及其用途
CN113876729B (zh) *	2021-11-11	2023-05-30	南通联亚药业股份有限公司	一种盐酸普拉克索缓释片剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US15735A (en) *		1856-09-16		Improvement in harvesters
US2887440A (en) *	1957-08-12	1959-05-19	Dow Chemical Co	Enteric coating
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja)	1975-07-24	1983-01-06	武田薬品工業株式会社	Ｌ− アスコルビンサンセイザイノセイゾウホウ
US4140755A (en)	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
CH649215A5 (de)	1981-04-29	1985-05-15	Hoffmann La Roche	Pharmazeutische praeparate.
SE8103843L (sv)	1981-06-18	1982-12-19	Astra Laekemedel Ab	Farmaceutisk mixtur
US4424235A (en)	1981-09-14	1984-01-03	Hoffmann-La Roche Inc.	Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
EP0186087B1 (de)	1984-12-22	1989-08-23	Dr. Karl Thomae GmbH	Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3447075A1 (de) *	1984-12-22	1986-07-03	Dr. Karl Thomae Gmbh, 7950 Biberach	Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US4738851A (en)	1985-09-27	1988-04-19	University Of Iowa Research Foundation, Inc.	Controlled release ophthalmic gel formulation
US4709712A (en)	1986-10-22	1987-12-01	Dermatalogical Products Of Texas	Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en)	1988-12-01	1989-01-05	Unilever Plc	Topical composition
US5026559A (en)	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
AU626427B2 (en)	1989-06-09	1992-07-30	Pharmacia & Upjohn Company	Heterocyclic amines having central nervous system activity
US5273975A (en)	1989-06-09	1993-12-28	The Upjohn Company	Heterocyclic amines having central nervous system activity
GB9015822D0 (en)	1990-07-18	1990-09-05	Beecham Group Plc	Compositions
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) *	1992-04-29	1997-08-12	Warner-Lambert Company	Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en)	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) *	1994-03-02	1995-10-17	Andrx Pharmaceuticals, Inc.	Controlled release tablet formulation
WO1997004752A1 (en) *	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
EP0998271B3 (en)	1997-06-06	2014-10-29	Depomed, Inc.	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
NZ513456A (en)	1997-07-01	2003-02-28	Pfizer	Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
US5895663A (en)	1997-07-31	1999-04-20	L. Perrigo Company	Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) *	1997-08-14	1999-02-14	Francois Carriere	Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US6248358B1 (en)	1998-08-25	2001-06-19	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en)	1998-08-25	2003-09-23	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
DE69819748T2 (de)	1997-09-12	2004-09-30	Columbia Laboratories (Bermuda) Ltd.	Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US7153845B2 (en)	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US6197339B1 (en) *	1997-09-30	2001-03-06	Pharmacia & Upjohn Company	Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) *	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
GB9802201D0 (en) *	1998-02-03	1998-04-01	Cerestar Holding Bv	Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
CA2323177A1 (en) *	1998-03-11	1999-09-16	Susan Marie Milosovich	Composition
GB9812426D0 (en)	1998-06-10	1998-08-05	Reckitt & Colmann Prod Ltd	Improvements in or relating to organic compositions
TW407058B (en) *	1998-07-17	2000-10-01	Dev Center Biotechnology	Oral cisapride dosage forms with an extended duration
DE19906290A1 (de)	1999-02-15	2000-08-17	Falk Pharma Gmbh	Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en)	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
WO2000059477A1 (en)	1999-03-31	2000-10-12	Janssen Pharmaceutica N.V.	Pregelatinized starch in a controlled release formulation
DE19927688A1 (de) *	1999-06-17	2000-12-21	Gruenenthal Gmbh	Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
PL196996B1 (pl)	1999-07-01	2008-02-29	Upjohn Co	Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
AP2002002410A0 (en)	1999-08-04	2002-03-31	Ranbaxy Laboratories Ltd	Hydrodynamically Balancing Oral Drug Delivery System
CO5210862A1 (es)	1999-09-15	2002-10-30	Alza Corp	Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
CA2384840A1 (en)	1999-09-30	2001-04-05	The General Hospital Corporation	Use of pramipexole as a treatment for cocaine craving
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PL355391A1 (en) *	1999-12-22	2004-04-19	Pharmacia Corporation	Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6467637B2 (en)	2000-01-27	2002-10-22	The York Group, Inc.	Death care merchandising system
JP2003523382A (ja)	2000-02-24	2003-08-05	ファルマシア・アンド・アップジョン・カンパニー	新規な薬物の組合せ
US6277875B1 (en) *	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
ES2187249B1 (es)	2000-09-18	2004-09-16	Synthon Bv	Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv)	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
DE10138275A1 (de)	2001-08-10	2003-02-27	Boehringer Ingelheim Pharma	Verbindungen zur Beseitigung der Anhedonie
WO2003053402A1 (en)	2001-12-20	2003-07-03	Pharmacia Corporation	Zero-order sustained released dosage forms and method of making the same
PE20040134A1 (es)	2002-07-25	2004-03-06	Pharmacia Corp	Forma de dosificacion de una vez al dia de pramipexol
AR040680A1 (es)	2002-07-25	2005-04-13	Pharmacia Corp	Composicion de tabletas de liberacion sostenida
BR0312876A (pt)	2002-07-25	2005-06-28	Pharmacia Corp	Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
US20040121010A1 (en)	2002-10-25	2004-06-24	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
AU2003224467A1 (en)	2003-03-11	2004-09-30	Korea United Pharm, Inc.	Process for the preparing of hardcapsule formulation containing lansoprazole
WO2004087175A1 (en)	2003-04-04	2004-10-14	Pharmacia Corporation	Oral extended release compressed tablets of multiparticulates
US20050020589A1 (en)	2003-06-18	2005-01-27	Pfizer Inc.	Sustained-release tablet composition comprising a dopamine receptor agonist
NZ553645A (en)	2004-08-13	2010-09-30	Boehringer Ingelheim Int	Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ589267A (en)	2004-08-13	2012-06-29	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006046256A1 (en)	2004-10-27	2006-05-04	Alembic Limited	Extended release formulation of pramipexole dihydrochloride
EP1901721A1 (en)	2005-06-23	2008-03-26	Spherics, Inc.	Delayed release or extended-delayed release dosage forms of pramipexole
US20080299204A1 (en)	2005-06-23	2008-12-04	Spherics, Inc.	Dosage forms for movement disorder treatment
JP2009504748A (ja)	2005-08-15	2009-02-05	ユニバーシティオブバージニアパテントファウンデーション	Ｒ（＋）プラミペキソールを用いた神経回復
WO2007054976A2 (en)	2005-11-08	2007-05-18	Panacea Biotec Ltd.	Lipid based controlled release pharmaceutical composition
US20090098202A1 (en)	2006-02-10	2009-04-16	Boehringer Ingelheim International Gmbh	Extended Release Formulation
CA2641665A1 (en)	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Modified release formulation
WO2007090882A2 (en)	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Pharmaceutical extended release compositions comprising pramipexole
EP1886665A1 (en)	2006-08-01	2008-02-13	Boehringer Ingelheim Pharma GmbH & Co. KG	Gastro retentive delivery system

2003
- 2003-07-23 US US10/626,166 patent/US20050226926A1/en not_active Abandoned
- 2003-07-24 PA PA20038578301A patent/PA8578301A1/es unknown
- 2003-07-24 MY MYPI20032784A patent/MY138846A/en unknown
- 2003-07-24 AR AR20030102666A patent/AR040681A1/es unknown
- 2003-07-24 PE PE2003000734A patent/PE20040130A1/es not_active Application Discontinuation
- 2003-07-25 CN CNB038178737A patent/CN1313092C/zh not_active Expired - Fee Related
- 2003-07-25 ES ES03771807T patent/ES2310673T3/es not_active Expired - Lifetime
- 2003-07-25 NZ NZ537790A patent/NZ537790A/en unknown
- 2003-07-25 ME MEP-523/08A patent/MEP52308A/hr unknown
- 2003-07-25 RS YU20050059A patent/RS51719B/sr unknown
- 2003-07-25 CA CA002492854A patent/CA2492854C/en not_active Expired - Fee Related
- 2003-07-25 GE GEAP8599A patent/GEP20074048B/en unknown
- 2003-07-25 TW TW092120406A patent/TWI347849B/zh not_active IP Right Cessation
- 2003-07-25 JP JP2004524787A patent/JP4700963B2/ja not_active Expired - Fee Related
- 2003-07-25 EP EP03771807A patent/EP1531814B1/en not_active Expired - Lifetime
- 2003-07-25 EA EA200702187A patent/EA200702187A1/ru unknown
- 2003-07-25 MX MXPA05001054A patent/MXPA05001054A/es active IP Right Grant
- 2003-07-25 OA OA1200500016A patent/OA13303A/en unknown
- 2003-07-25 SI SI200331350T patent/SI1531814T1/sl unknown
- 2003-07-25 AT AT03771807T patent/ATE406162T1/de active
- 2003-07-25 KR KR1020057001392A patent/KR100712832B1/ko not_active Expired - Fee Related
- 2003-07-25 PT PT03771807T patent/PT1531814E/pt unknown
- 2003-07-25 WO PCT/US2003/023205 patent/WO2004010997A1/en not_active Ceased
- 2003-07-25 DE DE60323235T patent/DE60323235D1/de not_active Expired - Lifetime
- 2003-07-25 HR HRP20041235AA patent/HRP20041235B1/hr not_active IP Right Cessation
- 2003-07-25 DK DK03771807T patent/DK1531814T3/da active
- 2003-07-25 EP EP08159203A patent/EP1987832A1/en not_active Withdrawn
- 2003-07-25 PL PL375696A patent/PL215587B1/pl unknown
- 2003-07-25 AP AP2005003205A patent/AP2201A/xx active
- 2003-07-25 AU AU2003261241A patent/AU2003261241B2/en not_active Ceased
- 2003-07-25 BR BR0312960-8A patent/BR0312960A/pt not_active IP Right Cessation
- 2003-07-25 EA EA200500079A patent/EA009663B1/ru not_active IP Right Cessation
- 2003-07-31 UY UY27912A patent/UY27912A1/es not_active Application Discontinuation
2004
- 2004-12-29 IS IS7623A patent/IS7623A/is unknown
- 2004-12-30 IL IL16607804A patent/IL166078A0/xx unknown
2005
- 2005-01-06 NO NO20050093A patent/NO334298B1/no not_active IP Right Cessation
- 2005-01-17 ZA ZA200500439A patent/ZA200500439B/xx unknown
- 2005-01-24 EC EC2005005568A patent/ECSP055568A/es unknown
- 2005-01-24 CR CR7661A patent/CR7661A/es unknown
- 2005-01-25 MA MA28066A patent/MA27328A1/fr unknown
- 2005-01-25 CU CU20050018A patent/CU23440B7/es not_active IP Right Cessation
- 2005-11-08 HK HK05109947A patent/HK10777456A1/xx unknown
2008
- 2008-10-13 CY CY20081101125T patent/CY1110408T1/el unknown
2010
- 2010-03-03 US US12/716,755 patent/US8399016B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW200418523A (en)	2004-10-01
NO20050093L (no)	2005-02-24
OA13303A (en)	2007-04-13
RS51719B (sr)	2011-10-31
CR7661A (es)	2005-06-08
HRP20041235B1 (hr)	2013-07-31
PL215587B1 (pl)	2013-12-31
JP2005538106A (ja)	2005-12-15
AU2003261241A1 (en)	2004-02-16
EP1987832A1 (en)	2008-11-05
IL166078A0 (en)	2006-01-15
RS20050059A (sr)	2007-08-03
WO2004010997A8 (en)	2005-02-24
ATE406162T1 (de)	2008-09-15
EA009663B1 (ru)	2008-02-28
GEP20074048B (en)	2007-02-26
CA2492854C (en)	2009-10-20
DE60323235D1 (de)	2008-10-09
PT1531814E (pt)	2008-10-29
ECSP055568A (es)	2005-04-18
WO2004010997A1 (en)	2004-02-05
CN1671382A (zh)	2005-09-21
ES2310673T3 (es)	2009-01-16
US20100316710A1 (en)	2010-12-16
MY138846A (en)	2009-07-31
MXPA05001054A (es)	2005-04-08
AR040681A1 (es)	2005-04-13
PL375696A1 (en)	2005-12-12
TWI347849B (en)	2011-09-01
PA8578301A1 (es)	2004-07-20
DK1531814T3 (da)	2008-10-13
KR20050062516A (ko)	2005-06-23
HRP20041235A2 (en)	2005-06-30
EP1531814B1 (en)	2008-08-27
NZ537790A (en)	2005-10-28
AP2201A (en)	2011-01-24
PE20040130A1 (es)	2004-03-06
AU2003261241B2 (en)	2009-06-18
EA200500079A1 (ru)	2005-06-30
AP2005003205A0 (en)	2005-03-31
SI1531814T1 (sl)	2008-12-31
KR100712832B1 (ko)	2007-04-30
US8399016B2 (en)	2013-03-19
CY1110408T1 (el)	2015-04-29
CA2492854A1 (en)	2004-02-05
CN1313092C (zh)	2007-05-02
HK10777456A1 (en)	2007-11-30
IS7623A (is)	2004-12-29
JP4700963B2 (ja)	2011-06-15
NO334298B1 (no)	2014-01-27
US20050226926A1 (en)	2005-10-13
UY27912A1 (es)	2004-02-27
EP1531814A1 (en)	2005-05-25
CU23440B7 (es)	2009-10-16
ZA200500439B (en)	2006-08-30
BR0312960A (pt)	2005-06-14
EA200702187A1 (ru)	2008-06-30
MA27328A1 (fr)	2005-05-02

Publication	Publication Date	Title
MEP52308A (hr)	2011-02-10	Kompozicija tablete pramipeksola sa produženim oslobođenjima
MY136318A (en)	2008-09-30	Sustained-release tablet composition
EA200900930A1 (ru)	2009-12-30	Композиция таблетки с пролонгированным высвобождением, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
JP2004518676A5 (hr)	2007-03-08
BR9917012A (pt)	2002-04-16	Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
DE69535445D1 (de)	2007-05-10	Schmelzextrudierte oral verabreichbare Opioidformulierungen
NO20016108D0 (no)	2001-12-14	Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
ATE303799T1 (de)	2005-09-15	Mikropartikel zum transport von arzneistoffen durch die schleimhaut und die blut-hirn-schranke
PL327395A1 (en)	1998-12-07	Method of making multiple-layer solid drug forms for oral or rectal administration
WO2002011694A3 (en)	2002-04-25	Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
NO20062111L (no)	2006-07-18	2-(3,4-dimetylfenyl)-4-{[2-hydroksy-3'(1H-tetrazol-5-yl)]-hydrazon}-5-metyl-2,4-dihydropyrozol-3-on kolin.
YU6401A (sh)	2004-03-12	Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene
ATE387100T1 (de)	2008-03-15	Calciumsalz enthaltender kaugummi
Ike-Nor et al.	2006	Evaluation of gellan gum as a potential pharmaceutical adjuvant: Binding properties in tablets containing a poorly water soluble and poorly compressible drug
WO2004058152A3 (en)	2004-09-16	An extended release pharmaceutical composition of phenytoin sodium
CO5680423A2 (es)	2006-09-29	Composicion de comprimido de liberacion sostenida de prami- presol
TNSN05020A1 (fr)	2007-05-14	Composition de pramipexole ne consistant pas en une composition de pramipexole a liberation prolongee
ATE408400T1 (de)	2008-10-15	Pharmazeutische zusammensetzung mit verzögerter freisetzung